Literature DB >> 18667493

Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a.

Zekuan Xu1, Xiaofeng Fan, Yanjuan Xu, Adrian M Di Bisceglie.   

Abstract

Viral breakthrough is a recognized response pattern to interferon-based antiviral therapy in patients with chronic hepatitis C virus (HCV) infection. The emergence of drug-resistant HCV quasispecies variants is assumed to be a major mechanism responsible for viral breakthrough. By using a long reverse transcription-PCR protocol recently developed in our lab, multiple nearly full-length HCV quasispecies variants were generated from 9.1-kb amplicons at both the baseline and breakthrough points in two patients experiencing viral breakthrough. Comparative analyses of consensus dominant quasispecies variants revealed that most mutations, occurring at the time of breakthrough, involved three functional viral genes, E2, NS2, and NS5a. Interestingly, similar mutation patterns were also observed in minor quasispecies variants at baseline. These three genes had the highest values of average amino acid complexity at the HCV 1a population level. No single amino acids were identified to be associated with viral breakthrough. Taken together, at the near-full-length HCV genome level, our data suggested that viral breakthrough might be attributed to the selection of minor quasispecies variants at the baseline with or without additional mutations during antiviral therapy. Furthermore, the pattern for mutation clustering indicated potential mutation linkage among E2, NS2, and NS5a due to structural or functional relatedness in HCV replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667493      PMCID: PMC2546966          DOI: 10.1128/JVI.00896-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

Authors:  M Nijhuis; R Schuurman; D de Jong; J Erickson; E Gustchina; J Albert; P Schipper; S Gulnik; C A Boucher
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

2.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

Authors:  D R Taylor; S T Shi; P R Romano; G N Barber; M M Lai
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

3.  Separation of near full-length hepatitis C virus quasispecies variants from a complex population.

Authors:  Donghui Zhou; Xiaofeng Fan; De Tan; Yanjuan Xu; John E Tavis; Adrian M Di Bisceglie
Journal:  J Virol Methods       Date:  2007-01-08       Impact factor: 2.014

Review 4.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Authors:  A J Hance; V Lemiale; J Izopet; D Lecossier; V Joly; P Massip; F Mammano; D Descamps; F Brun-Vézinet; F Clavel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Sampling and repeatability in the evaluation of hepatitis C virus genetic variability.

Authors:  Manuela Torres-Puente; M Alma Bracho; Nuria Jiménez; Inmaculada García-Robles; Andrés Moya; Fernando González-Candelas
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

7.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

8.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

9.  Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

Authors:  Charlotte Charpentier; Dominic E Dwyer; Fabrizio Mammano; Denise Lecossier; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.

Authors:  Kung-Chia Young; Karen L Lindsay; Ki-Jeong Lee; Wen-Chun Liu; Jian-Wen He; Susan L Milstein; Michael M C Lai
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

View more
  12 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

3.  Comprehensive cloning of patient-derived 9022-bp amplicons of hepatitis C virus.

Authors:  Yang Lu; Yanjuan Xu; Adrian M Di Bisceglie; Xiaofeng Fan
Journal:  J Virol Methods       Date:  2013-04-17       Impact factor: 2.014

4.  Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans.

Authors:  Rajeev Aurora; Maureen J Donlin; Nathan A Cannon; John E Tavis
Journal:  J Clin Invest       Date:  2008-12-22       Impact factor: 14.808

5.  Novel nucleotide and amino acid covariation between the 5'UTR and the NS2/NS3 proteins of hepatitis C virus: bioinformatic and functional analyses.

Authors:  Hung-Yu Sun; Nai-Ying Ou; Shainn-Wei Wang; Wen-Chun Liu; Ting-Fang Cheng; Shiou-Jiuan Shr; Koun-Tem Sun; Ting-Tsung Chang; Kung-Chia Young
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

6.  Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.

Authors:  Akihiro Nasu; Hiroyuki Marusawa; Yoshihide Ueda; Norihiro Nishijima; Ken Takahashi; Yukio Osaki; Yukitaka Yamashita; Tetsuro Inokuma; Takashi Tamada; Takeshi Fujiwara; Fumiaki Sato; Kazuharu Shimizu; Tsutomu Chiba
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

7.  Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.

Authors:  H J Yuan; M Jain; K K Snow; M Gale; W M Lee
Journal:  J Viral Hepat       Date:  2009-07-28       Impact factor: 3.728

8.  Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study.

Authors:  Wei Li; Dao-Ming Li; Kai Chen; Zheng Chen; Yang Zong; Hong Yin; Ze-Kuan Xu; Yi Zhu; Fei-Ran Gong; Min Tao
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

9.  Analysis of HCV quasispecies dynamic under selective pressure of combined therapy.

Authors:  Ana C G Jardim; Cíntia Bittar; Renata P A Matos; Lílian H T Yamasaki; Rafael A Silva; João R R Pinho; Roberta M Fachini; Claudia M A Carareto; Isabel M V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

10.  Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples.

Authors:  Eileen Z Zhang; Doug J Bartels; J Dan Frantz; Sheila Seepersaud; Judith A Lippke; Benjamin Shames; Yi Zhou; Chao Lin; Ann Kwong; Tara L Kieffer
Journal:  Virol J       Date:  2013-02-12       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.